Septerna, Inc.
SEPN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.01B
Close$
$-33.21
173.6% downside
Current Fair Value
173.6% downsideOvervalued by 173.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.01 Billion |
|---|---|
| Enterprise Value | $2.02 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.1 |
| Beta | 2.28 |
| Outstanding Shares | 45,040,075 |
Return
| Return on Equity | -6.27% |
|---|---|
| Return on Assets | -4.28% |
| Return on Invested Capital | -10.52% |
Valuation & Multiples
| P/E Ratio | -82.41 |
|---|---|
| PEG | 173.4 |
| Price to Sales | 22.57 |
| Price to Book Ratio | 5.64 |
| Enterprise Value to Revenue | 20.47 |
| Enterprise Value to EBIT | -39.48 |
| Enterprise Value to Net Income | -84 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.27 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
$19.22 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
$21.48 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 152▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 30.28%▼ 71.87% |
|---|---|
| Total Invested | $453.87M▼ 58.69% |
| Investors Holding | 42▼ 83.00% |
ESG Score
No data
About Septerna, Inc.
75 employees
CEO: Dr. Jeffrey T. Finer M.D., Ph.D. Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic disea...